BMJ1d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ2d
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Correspondence to Dr Laura C Cappelli, Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA; lcappel1{at}jhmi.edu Objective We sought to investigate the long-term outcomes of ...
BMJ1d
POS1328 DIFFERENTIATING “SCLERODERMA” WITH “NON-SCLERODERMA” PATTERNS IN NAILFOLD CAPILLARY MICROSCOPY USING A DEEP LEARNING MODEL
Background Nailfold capillary microscopy is used for diagnostic purposes in rheumatology since many years. Abnormal nailfold capillaries are also listed in the 2013 ACR/EULAR classification criteria ...
BMJ2d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ2d
SAT0073 MIR-186-5P targeting IL-33 gene as biomarker to predict subclinical atherosclerosis in patients with early rheumatoid arthritis
Background Patients with rheumatoid arthritis (RA) die prematurely compared with the general population, primarily because of cardiovascular diseases (CVD). Interleukin-33 (IL-33) is a member of the ...
BMJ7d
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
Objectives To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and ...
BMJ5d
Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological ...
BMJ1d
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis
Objective Innate lymphoid cells-2 (ILC2) were shown to be involved in the development of lung or hepatic fibrosis. We sought to explore the functional and phenotypic heterogeneity of ILC2 in skin ...
BMJ7d
EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis
15 Department of Radiology. Leiden University Medical Centre, Leiden, The Netherlands 16 Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ10d
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
Correspondence to Mrs Eloisa Bonfa, Rheumatology Division, Universidade de Sao Paulo Faculdade de Medicina, Sao Paulo, São Paulo, Brazil; eloisa.bonfa{at}hc.fm.usp.br Objectives To evaluate the ...
BMJ8d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ10d
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This ...